European Investment Bank Provides $26.7MM Venture Debt Financing to ExeVir Bio
ExeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, secured a venture debt financing agreement of up to €25 million ($26.7 million) with the European Investment Bank.
January 9, 2023
Dr. Torsten Mummenbrauer | European Investment Bank | ExeVir Bio | Fiona du Monceau | Kris Peeters
Ian Koplin